Quest Diagnostics’ Retrenchment Gives Royalty Pharma A Stake In Ibrutinib
This article was originally published in The Pink Sheet Daily
Executive Summary
The royalty stream investor now has a stake in the highly anticipated cancer treatment that was recently submitted to FDA. The sale of the revenue stream is just another step in Quest’s efforts to refocus the company.
You may also be interested in...
Onyx Starts Acquisition Process; Price And Competition To Come Into Play
The fast-growing biotech is soliciting bids, after a rejected Amgen offer and additional third party interest. Wall Street is scrambling to determine how to value Onyx and who the bidders could be.
Elan Prepares For A Buying Spree Now That Biogen Has Taken Over Tysabri
Biogen Idec announced Feb.6 that it will pay $3.25 billion to its partner Elan for full rights to the multiple sclerosis drug Tysabri. The deal was not a surprise to Biogen investors, but it leaves Elan with a war chest of cash and virtually no commercial assets.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.